#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Alveolar rhabdomyosarcoma Lymphatic malformation Congenital cystic kidney disease Pancreatic carcinoma metastatic Myeloproliferative neoplasm Fibrosarcoma metastatic Non-Hodgkin's lymphoma unspecified histology aggressive recurrent Emphysema Red blood cell abnormality Peripheral T-cell lymphoma unspecified Biotinidase deficiency Epidermolysis bullosa Bile acid synthesis disorder High-grade B-cell lymphoma Uveal melanoma More trials…

    Learn about Rare Diseases

    Antisynthetase syndrome Epidermolysis bullosa – Treatment Osteosarcoma – Life with Disease Acute respiratory distress syndrome Marginal zone lymphoma refractory – Life with Disease Leiomyosarcoma metastatic – Basic Information Myelodysplastic syndrome with excess blasts – Trials in Disease Ocular melanoma – Trials in Disease Mitochondrial myopathy – Diagnostics Krabbe’s disease – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Avibactam Sodium Remifentanil Avutometinib Pegfilgrastim Thiamazole INCB123667 Ro7589655 Specific Nucleic Acid Sna-Xfsa Valiltramiprosate LIGUFALIMAB Lamivudine Pertechnetate (99Mtc) Sodium Dabrafenib Mesylate Poa Pratensis Pollen Extract Thymalfasin Acetic Acid, Glacial Ceftazidime Elebsiran Sodium Zirconium Cyclosilicate Levothyroxine More therapies…

    Learn about Your Condition

    Back pain Retroperitoneal cancer Cardiogenic shock Immune thrombocytopenia Paraganglion neoplasm Influenza Myocardial ischaemia Nicotine dependence Intermittent claudication Combined immunodeficiency Scoliosis Partial lipodystrophy Cystic fibrosis Salivary gland cancer Brain neoplasm malignant More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Small cell lung cancer

  • Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Topotecan Hydrochloride
    Austria Belgium Czechia Denmark France Germany +5

  • BMS-986525 Alone and with Nivolumab in Patients with Relapsed or Refractory Small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Small cell lung cancer
    Investigated Drugs:
    • Nivolumab
    Italy Romania Spain

  • A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Atezolizumab
    • Carboplatin
    • Etoposide
    Austria Belgium Bulgaria Czechia Estonia Finland +14

  • A study to evaluate the effectiveness of tarlatamab in patients with extensive-stage small cell lung cancer that has progressed after prior treatment and who have limited health status

    Recruiting

    2 1 1
    Investigated Diseases:
    • Lung neoplasm malignant
    • Small cell lung cancer
    • Small cell lung cancer extensive stage
    Investigated Drugs:
    • Tarlatamab
    France Greece Italy Spain

  • A study to investigate the safety and effects of ceralasertib, tremelimumab, and durvalumab in adults with various solid tumors

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Hyaluronidase (Human Recombinant)
    • Tremelimumab
    • Durvalumab
    Poland

  • A study of ABBV-706 and atezolizumab for patients with previously untreated extensive stage small cell lung cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Small cell lung cancer
    Investigated Drugs:
    • Atezolizumab
    • Carboplatin
    • Etoposide
    Belgium Germany Italy Poland Spain
1 2 3 … 6
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!